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Abstract
Introduction Hyperlactatemia during cardiopulmonary bypass
is relatively frequent and is associated with an increased
postoperative morbidity. The aim of this study was to determine
which perfusion-related factors may be responsible for
hyperlactatemia, with specific respect to hemodilution and
oxygen delivery, and to verify the clinical impact of
hyperlactatemia during cardiopulmonary bypass in terms of
postoperative morbidity and mortality rate.
Methods Five hundred consecutive patients undergoing
cardiac surgery with cardiopulmonary bypass were admitted to
this prospective observational study. During cardiopulmonary
bypass, serial arterial blood gas analyses with blood lactate and
glucose determinations were obtained. Hyperlactatemia was
defined as a peak arterial blood lactate concentration exceeding
3 mmol/l. Pre- and intraoperative factors were tested for
independent association with the peak arterial lactate
concentration and hyperlactatemia. The postoperative outcome
of patients with or without hyperlactatemia was compared.
Results Factors independently associated with hyperlactatemia
were the preoperative serum creatinine value, the presence of
active endocarditis, the cardiopulmonary bypass duration, the
lowest oxygen delivery during cardiopulmonary bypass, and the
peak blood glucose level. Once corrected for other explanatory
variables, hyperlactatemia during cardiopulmonary bypass
remained significantly associated with an increased morbidity,
related mainly to a postoperative low cardiac output syndrome,
but not to mortality.
Conclusion Hyperlactatemia during cardiopulmonary bypass
appears to be related mainly to a condition of insufficient oxygen
delivery (type A hyperlactatemia). During cardiopulmonary
bypass, a careful coupling of pump flow and arterial oxygen
content therefore seems mandatory to guarantee a sufficient
oxygen supply to the peripheral tissues.
Introduction
Hyperlactatemia (HL) is a well-recognized marker of circula-
tory failure, and its severity has been associated with mortality
in different clinical conditions [1,2]. After cardiac surgery, HL
is relatively common [3,4] and is associated with morbidity and
mortality [4]. During cardiac surgery with cardiopulmonary
bypass (CPB) in adult patients, HL is detectable at a consid-
erable (10% to 20%) rate [5,6] and is associated with postop-
erative morbidity and mortality [5]. At present, the nature of HL
during and after cardiac operations is not totally clear, but the
majority of authors [4,7-9] tend to attribute this finding to a tis-
sue hypoxia (type A HL) even if type B HL (without tissue
hypoxia) has been advocated in some cases [10]. The main
factors leading to a possible organ dysoxia during CPB are the
hemodilution degree [11,12] and a low peripheral oxygen
delivery (Do2) [13]. Both have been associated with postoper-
ative morbidity and mortality. Hence, there is a consistent body
of information suggesting that during CPB an unrecognized
pattern of critically decreased peripheral oxygen supply may
occur and that, as a result of this condition of circulatory fail-
ure, lactate production appears. As a matter of fact, the con-
cept of critical Do2 is based on the assumption that when a
patient is perfused below the critical value, the oxygen con-
sumption (Vo2) becomes dependent on the Do2 [14-16] and
CPB = cardiopulmonary bypass; Do2 = oxygen delivery; HCT = hematocrit; HL = hyperlactatemia; ICU = intensive care unit; MV = mechanical ven-
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energy production is partially supplied by anaerobic glycolysis.
As a result, lactate production increases and HL takes its
course [17,18].
Despite this apparently reasonable assumption, no scientific
evidence of an association between HL and oxygen supply
during CPB is available. Even the association between HL dur-
ing CPB and postoperative morbidity/mortality is far from
being well defined, the only report being based on a retrospec-
tive study [5]. The present study was designed with two end-
points: (a) to define the factors associated with HL during
CPB, specifically with respect to perfusion-related factors dur-
ing CPB, and (b) to verify the clinical impact of HL during CPB
in terms of postoperative morbidity and mortality.
Materials and methods
Study design
This was a prospective observational study conducted at our
institution from September 1 2005 to December 22 2005.
The study design did not include any intervention, and data
collection was based on the local database and routine meas-
urements performed during the operation. Therefore, the local
ethical committee waived the need for approval. All of the
patients gave written consent to the scientific treatment of
their data.
Patient population
Five hundred consecutive adult patients (age > 18 years)
undergoing cardiac surgery operations were admitted to this
study. No operation-based selection was applied (excluding
cardiac transplantation that is not performed at our institution).
The only exclusion criterion was the presence of an abnormal
(> 2 mmol/l) plasma lactate value before entering CPB. This
condition, generally associated with emergency procedure,
unstable preoperative hemodynamics, and pre- or intraopera-
tive need for inotropic support or intra-aortic balloon pump,
was detected in 30 patients, who were therefore excluded
from the subsequent analyses. The remaining 470 patients
were analyzed according to the purposes of the study.
Anesthesia, surgery, and CPB management
Premedication included atropine sulphate (0.5 mg), pro-
metazine (50 mg), and fentanyl (50 to 100 μg according to the
patient's weight) intramuscularly administered one hour before
the induction of anesthesia. Anesthesia was induced with an
intravenous infusion of remifentanil (starting dose 0.5 μg/kg
per minute) and a midazolam bolus of 0.2 mg/kg. Cisatracu-
rium besylate (0.2 mg/kg) was subsequently administered to
allow tracheal intubation. Subsequently, the anesthesia was
maintained with a continuous infusion of remifentanil (dose
ranging from 0.05 to 1 μg/kg per minute, titrated on the basis
of the hemodynamic response) and midazolam (0.1 mg/kg per
hour).
CPB was established via a standard median sternotomy, aor-
tic root cannulation, and single or double atrial cannulation for
venous return. Lowest core body temperature during CPB var-
ied from 27°C to 37°C as requested by the surgeon. Ante-
grade intermittent cold crystalloid or cold blood cardioplegia
was used according to the surgeon's preference. The circuit
was primed with 700 ml of a gelatin solution (Medacta Italia,
Milan, Italy) and 200 ml of trihydroxymethylaminomethane
solution. Roller (Stöckert, now part of Sorin Group Deutsch-
land GmbH, München, Germany) or centrifugal (Medtronic,
Inc., Minneapolis, MN, USA) pumps were used according to
availability; a biocompatible treatment (phosphorylcholine
coating) and a closed circuit with separation of the blood suc-
tions were used in 20% of the patients. The oxygenator was a
hollow fiber D 905 Avant (Dideco, now part of Sorin Group Ita-
lia S.r.l. Mirandola, Italy). The pump flow was targeted between
2.0 and 2.4 l/minute per m2 and the target mean arterial pres-
sure was settled at 60 mm Hg. The gas flow was initially set-
tled at 50% oxygen/air ratio and a 1:2 flow ratio with the pump
flow indexed and was subsequently arranged in order to main-
tain an arterial oxygen tension greater than 150 mm Hg and an
arterial carbon dioxide tension between 33 and 38 mm Hg.
Anticoagulation was established with an initial dose of 300 IU
per kilogram of body weight of porcine intestinal heparin
injected into a central venous line ten minutes before the initi-
ation of CPB and with a target activated clotting time of 480
seconds; patients receiving closed and biocompatible circuits
received a reduced dose of heparin with a target activated
clotting time settled at 300 seconds. At the end of CPB,
heparin was reversed by protamine chloride at a 1:1 ratio of
the loading dose, regardless of the total heparin dosage.
Data collection and definitions
The following preoperative data were collected and analyzed:
demographics (age [years], gender, weight [kg], and height
[cm]), preoperative cardiovascular profile (ejection fraction,
New York Heart Association functional class, recent [30 days]
myocardial infarction, unstable angina, congestive heart fail-
ure, previous vascular surgery, previous cardiac surgery, car-
diogenic shock, use of intra-aortic balloon pump, and active
endocarditis), presence of comorbidities (chronic renal failure,
diabetes on medication, chronic obstructive pulmonary dis-
ease, and cerebrovascular accident), and laboratory assays
(serum creatinine value [mg/dl] and hematocrit [HCT]
[percentage]).
Operative data comprised type of operation (isolated coronary
artery bypass graft, isolated valve procedure, and combined
operation), CPB duration (minutes), lowest temperature (°C),
and lowest pump flow indexed reached on CPB. At the onset
of CPB and every 20 minutes, an arterial blood gas analysis,
including blood glucose (mg/dl) and lactate (mmol/l) determi-
nation, was obtained. Blood gas analyses were performed
using a Nova Stat Profile blood gas analyzer (Nova BiomedicalAvailable online http://ccforum.com/content/10/6/R167
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Corporation, Waltham, MA, USA). On the basis of the arterial
blood data, we assessed the lowest HCT (percentage) on
CPB, the lowest Do2 (ml/minute per m2) on CPB (calculated
according to standard equations on the basis of arterial hemo-
globin concentration and saturation and on pump flow
indexed), the peak blood glucose, and the peak lactate
concentration.
Outcome variables included time on mechanical ventilation
(MV) (hours), intensive care unit (ICU) stay (days), postopera-
tive hospital stay (days), peak postoperative serum creatinine
level (mg/dl), surgical revision rate, perioperative myocardial
infarction rate (new Q waves plus enzymatic criteria), low car-
diac output syndrome, atrial fibrillation rate (not pre-existing),
presence of ventricular arrhythmias, acute renal failure (requir-
ing renal replacement therapy), stroke, severe pulmonary dys-
function, cardiac arrest, sepsis, composite morbidity index
(one of the following major complications: surgical reopera-
tion, need for intra-aortic balloon pump, stroke, acute renal fail-
ure, or sepsis), and hospital mortality rate. In accordance with
previous studies [4,6], HL was defined as a peak blood lactate
value greater than 3 mmol/l.
Statistical analysis
All data are expressed as mean ± standard error of the mean
or as absolute numbers and percentage when appropriate. A
p value less than 0.05 was considered significant for all of the
following statistical tests. The statistical analysis was per-
formed using SPSS 11.0 software (SPSS Inc., Chicago, IL,
USA).
Univariate association with peak blood lactate was tested with
a correlation matrix. Factors significantly (p < 0.05) associated
with the peak blood lactate at this preliminary step were
entered into a stepwise forward multivariable linear regression
analysis, with adequate corrections to avoid multicollinearity
within the model. The multivariable approach was applied to
assess the independent association between the variables
tested and the peak blood lactate. Subsequently, the popula-
tion was explored in terms of HL (> 3 mmol/l) incidence.
A graphical analysis of the relationship between intraoperative
variables and peak blood lactate value was performed using a
non-linear regression analysis based on the technique of 'roll-
ing decile' subgroups [11,19]. This technique is based on the
following steps: (a) the patient population is ordered accord-
ing to the independent variable tested (lowest Do2 on CPB,
peak blood glucose, and CPB duration), (b) the population is
divided into deciles and subsequently into 37 rolling deciles
(having 75% overlapping ranges), (c) the mean value of the
independent variables and the corresponding mean value of
the peak blood lactates are calculated, and (d) the 37 points
are plotted separately for the three independent variables. The
rationale for this approach is to create a clear graphical rela-
tionship avoiding the difficult and confounding use of a stand-
ard plot of the original 470 experimental points. The patient
population was arranged in order of increasing peak blood glu-
cose levels, lowest Do2, and CPB duration, and a total of 37
subgroups (75% overlapping ranges) were analyzed with
respect to the HL incidence. The same three intraoperative
variables were tested for predictivity of HL by using a receiver
operating characteristic (ROC) analysis. Postoperative out-
come was firstly analyzed in the population with or without HL
during CPB by using a univariate approach (Student's t test for
unpaired data or relative risk analysis) and was subsequently
corrected for other covariates in a multivariable linear or logis-
tic regression analysis.
Results
Preoperative profile and operative data of the patient popula-
tion are reported in Table 1.
Twelve pre- and intraoperative factors were found to be signif-
icantly associated with the peak blood lactate level during
CPB at the univariate analysis (Table 2). Age, ejection fraction,
isolated coronary operation, lowest pump flow, lowest temper-
ature, HCT, and Do2 during CPB were negatively correlated to
the peak blood lactate value during CPB. Presence of active
endocarditis and congestive heart failure, preoperative serum
creatinine level, CPB duration, and peak blood glucose during
CPB were positively correlated to the peak blood lactate value
during CPB.
Some of these factors demonstrated a significant intercorrela-
tion (ejection fraction with congestive heart failure; lowest
pump flow and lowest HCT with the lowest Do2 during CPB).
To avoid multicollinearity, the most significant factors (ejection
fraction and Do2 during CPB) were included in the multivaria-
ble analysis, whereas the others were discharged. In the
resulting multivariable stepwise forward linear regression anal-
ysis (Table 2), five factors remained independently associated
with the peak blood lactate value (preoperative serum creati-
nine level, presence of active endocarditis, CPB duration, low-
est Do2 during CPB, and peak blood glucose level during
CPB). The last three factors were explored using a rolling
decile graphical analysis (Figure 1). When analyzed with best-
fit equations, quadratic non-linear regressions demonstrated
the best fit.
The same intraoperative factors were tested for predictivity of
HL (Table 3) with an ROC analysis. The area under the curve
was significant for all three factors. However, no cutoff value
could be detected for the lowest Do2 during CPB; conversely,
cutoff values of 96 minutes for CPB duration (sensitivity 74%,
specificity 80%) and of 160 mg/dl for peak blood glucose on
CPB (sensitivity 84%, specificity 83%) were found.
HL was detected in 27 (5.7%) patients, and hyperglycemia (>
160 mg/dl) in 92 (19.6%). The patient population was ana-
lyzed according to the presence of HL, hyperglycemia, or both,Critical Care    Vol 10 No 6    Ranucci et al.
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with respect to the peak blood lactates and to the lowest Do2
on CPB (Table 4). Patients without HL or hyperglycemia had
significantly lower values of peak blood lactate than the other
three groups; patients with both HL and hyperglycemia had
significantly higher peak blood lactate values than patients
with only HL or hyperglycemia. Only the patients with associ-
ated HL and hyperglycemia had significantly lower values of
Do2 on CPB.
Outcome variables associated with the presence of HL during
CPB were MV time and need for prolonged (> 48 hours) MV,
ICU stay and need for prolonged (> 7 days) ICU stay, postop-
erative peak serum creatinine level, need for surgical revision,
need for intra-aortic balloon pump, incidence of atrial fibrilla-
tion, severe lung dysfunction, sepsis, composite morbidity
index, and hospital mortality (Table 5). The univariate model
was then corrected for the other covariates determining the
peak blood lactate value (preoperative serum creatinine value,
presence of active endocarditis, and CPB duration). After cor-
rection in a multivariable linear or logistic regression analysis,
the outcome variables significantly associated with HL during
CPB were ICU stay, need for intra-aortic balloon pump, and
the composite morbidity index. Patients with HL during CPB
had a significantly higher rate of prolonged MV time and ICU
Table 1
Preoperative profile and operative data
Variable Number (percentage)
or
mean ± standard deviation
Age (years) 64.5 ± 14.2
Male gender 324 (69)
Body surface area (m2) 1.81 ± 0.18
Left ventricle ejection fraction 0.51 ± 0.12
Unstable angina 36 (7.7)
Previous vascular surgery 19 (4.1)
Previous cardiac surgery 39 (8.3)
Recent myocardial infarction 113 (24)
Congestive heart failure 30 (6.4)
Cardiogenic shock 5 (1.1)
Preoperative intra-aortic balloon pump 4 (0.8)
Active endocarditis 7 (1.5)
Dialytic treatment 4 (0.8)
Diabetes on medication 56 (12)
Chronic obstructive pulmonary disease 19 (4.1)
Previous cerebrovascular accident 33 (7)
Hematocrit (percentage) 39.8 ± 4.6
Serum creatinine value (mg/dl) 1.1 ± 0.8
Isolated coronary operation 211 (45)
Isolated valve operation 138 (29)
Combined operation 121 (26)
CPB duration (minutes) 81 ± 41
Lowest hematocrit on CPB (percentage) 27 ± 3.5
Lowest oxygen delivery on CPB (ml/minute per m2)2 9 1  ±  4 4
Lowest temperature on CPB (°C) 31 ± 1.9
Peak blood lactate (mmol/l) 1.5 ± 1.3
Peak blood glucose (mg/dl) 133 ± 47
CPB, cardiopulmonary bypass.Available online http://ccforum.com/content/10/6/R167
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stay (Table 5). Patients with hyperglycemia not associated
with HL were separately investigated for the outcome varia-
bles. No significant differences in terms of morbidity or mortal-
ity were detected in association with this isolated condition.
Discussion
The main findings of our study are that HL during CPB (a) is
more likely to occur in procedures requiring a prolonged CPB
time, (b) appears to be independently associated with a low
Do2, (c) is almost invariably associated with hyperglycemia,
and (d) is a marker of a worse postoperative outcome in terms
of morbidity, even if it is not significantly associated with an
increased mortality rate.
The rate of patients demonstrating HL during CPB was rela-
tively low (5.7%). However, in this study, we focused on HL
progressively established during CPB and excluded 30
patients who entered CPB with a pre-existing HL. The overall
incidence of HL was 11.4%, which is still lower than the one
reported by previous studies [5].
Various preoperative factors or comorbidities may create the
right environment for HL during CPB. Age, female gender,
congestive heart failure, low left ventricular ejection fraction,
hypertension, atherosclerosis, diabetes, preoperative hemo-
globin value, redo or complex surgery, and emergency proce-
dures were found to be risk factors for HL by Demers and
coworkers [5], who reported an HL incidence of 18%. Some
of these factors were confirmed in our study, and other new
factors were identified; however, our study population had a
significantly shorter CPB duration and a lower degree of
hemodilution during CPB. Given that both these factors seem
to favor the onset of HL, the lower HL rate in our population is
reasonably explained.
Table 2
Univariate and multivariable analyses for pre- and intraoperative factors associated with peak blood lactate value
Univariate analysis (correlation matrix)
Factor Correlation coefficient p value
Age (years) -0.099 0.032
Ejection fraction -0.181 0.001
Congestive heart failure 0.191 0.001
Preoperative serum creatinine value (mg/dl) 0.191 0.001
Active endocarditis 0.177 0.001
Isolated coronary operation -0.094 0.041
CPB duration (minutes) 0.523 0.001
Lowest temperature (°C) on CPB -0.312 0.001
Lowest hematocrit on CPB -0.158 0.001
Lowest pump flow (l/minute per m2) on CPB -0.271 0.001
Lowest Do2 (ml/minute per m2) on CPB -0.276 0.001
Peak blood glucose (mg/dl) on CPB 0.517 0.001
Multivariable analysis (linear regression)
Factor B coefficient p value
Constant 0.326
Preoperative serum creatinine value (mg/dl) 0.123 0.032
Active endocarditis 0.177 0.001
CPB duration (minutes) 0.012 0.001
Lowest Do2 (ml/minute per m2) on CPB -0.004 0.004
Peak blood glucose (mg/dl) on CPB 0.009 0.001
CPB, cardiopulmonary bypass; Do2, oxygen delivery.Critical Care    Vol 10 No 6    Ranucci et al.
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The role of CPB duration in the determinationof HL during
CPB has been highlighted by other authors [5]. In fact, the
association between CPB duration and peak blood lactate
level is not linear: we could identify a cutoff value of 96 minutes
as predictive of HL during CPB.
On the basis of our data, the main rationale for explaining HL
during CPB is a Do2 inadequate to guarantee the needed Vo2
of the patient. The association between the lowest Do2 during
CPB and HL is maintained within a multivariable model, and
the predictivity of the lowest Do2 is confirmed by the ROC
analysis. We could not identify a specific cutoff value, but from
the graphical relationship obtained using the rolling decile
technique, the value of Do2 below which the peak blood lac-
tate starts increasing is approximately 260 ml/minute per m2.
There are no previous studies addressing Do2 and lactate lev-
els during CPB. However, Demers and coworkers [5] found
that a low hemoglobin level during CPB is associated with HL,
and it is reasonable to interpret this information within the con-
text of a low Do2 during CPB.
The link between Do2 and HL definitely defines HL during CPB
as type A HL. It appears reasonable that under certain circum-
stances (favored by some preoperative comorbidities) and in
the presence of a prolonged CPB, the Do2 may decrease
below a critical level, the Vo2 becomes dependent on the Do2
and starts decreasing, and lactic acidosis is established.
Interestingly, in a previous study [13], we could demonstrate
that the incidence of acute renal failure after cardiac
operations is significantly increased in patients perfused
below the critical Do2 value of 272 ml/minute per m2, a figure
that appears to be in agreement with the data of the present
study. This information, together with the well-known associa-
tion between severe hemodilution during CPB and bad out-
comes [11,12], reinforces the interpretation that patients with
HL during CPB are suffering from a sort of masked circulatory
shock, which will exert its deleterious effects on different
organs (mainly on renal function) during the early phases of the
postoperative course.
The association between hyperglycemia and HL may be inter-
preted within this model of circulatory failure during CPB. In a
model of cardiogenic shock after heart surgery, Chioléro and
coworkers [20] could demonstrate that HL is due mainly to
increased production rather than to impaired lactate use. HL
was almost invariably accompanied by hyperglycemia due
mainly to increased glucose production, which was probably
due to the release of stress hormones and cytokines leading
to insulin resistance [21]. The extra amount of glucose fails to
enter the oxidative pathway and is degraded to lactate by the
glycolytic pathway.
Figure 1
Peak arterial blood lactate value during cardiopulmonary bypass  according to the cardiopulmonary bypass duration, the lowest oxygen  delivery, and the peak blood glucose Peak arterial blood lactate value during cardiopulmonary bypass 
according to the cardiopulmonary bypass duration, the lowest oxygen 
delivery, and the peak blood glucose. Data are shown as rolling deciles 
(75% overlapping). Symbols (open boxes) represent the mean value 
recorded for each decile.Available online http://ccforum.com/content/10/6/R167
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In our model, a possible interpretation is that a reduced Do2
due to insufficient pump flow, severe hemodilution, or both
creates a condition similar to a cardiogenic shock, leading on
one side to a direct lactate formation by the dysoxic organs
and on the other to a catecholamine release, insulin resist-
ance, hyperglycemia, and lactate formation (with subsequent
liver uptake and reconversion to glucose by the Cori cycle).
The link between HL and hyperglycemia through the mecha-
nism explained above was confirmed by the same group of
researchers in 2005 [22] in an elegant study dealing with car-
diogenic or septic shock. The role of adrenergic agonists in
this setting is well defined: in cardiogenic shock, they are both
endogenous or administered for cardiovascular therapy; in our
model, they are endogenous in the majority of the patients.
None received epinephrine during CPB, and few received
norepinephrine; however, unlike epinephrine, norepinephrine
usually does not increase glucose production or induce an
increase in plasma lactate concentration [23].
The two mechanisms leading to HL in various clinical condi-
tions are therefore (a) anaerobic metabolism due to a poor Do2
and (b) excess lactate production due to glucose failing to
enter the oxidative pathway and being degraded to lactate by
the glycolytic pathway. These mechanisms, if independently
considered, lead to different acid-base balance conditions, the
former being accompanied by metabolic acidosis and the lat-
ter not necessarily so. However, in the clinical conditions of
this observational study, the acid-base balance is constantly
maintained at a normal pH value by bicarbonate corrections
applied by the perfusionist whenever the base excess starts
decreasing. Therefore, we are unable to identify differences in
pH related to different values of peak blood lactates. However,
the evidence that only four patients demonstrated HL without
hyperglycemia and that only patients with an HL-hyperglyc-
emia syndrome had a significantly lower value of Do2 seems to
confirm that, in our specific clinical environment, HL and hyper-
glycemia are linked by the causative factor of a poor Do2, lead-
ing on one side to lactate production through the anaerobic
pathway and on the other to a vicious cycle of lactate produc-
tion due to the poor ability to use glucose through the aerobic
pathway.
Whenever the Do2 decreases, compensatory mechanisms are
usually triggered to maintain the Vo2 through a higher oxygen
extraction. Consequently, the mixed venous oxygen saturation
(Svo2) decreases. The measurement of the Svo2 is possible
during CPB, but very rarely is it routinely performed using on-
line measurement devices in adult patients. Mixed venous
blood gas analyses were available in our experimental setting
but not at any arterial blood gas analysis time point. Therefore,
in this study, we cannot address the association between Svo2
and blood lactates. However, in a previous study, we could
demonstrate that under CPB conditions the correlation
between the two variables was very poor [6].
In our series, HL during CPB leads to an increased morbidity
that, after correction for other explanatory variables, appears to
be related mainly to a low cardiac output state. This increased
morbidity leads in turn to prolonged MV and ICU stay. Con-
versely, mortality is not significantly associated with HL.
Only one article addresses the association between HL during
CPB and postoperative outcome [5]. In that work, HL was sig-
Table 3
Receiver operating characteristic analysis for the three intraoperative predictors of hyperlactatemia
Factor AUC 95% CI p value Cutoff value Sensitivity Specificity
Lowest Do2 on CPB 0.70 0.55–0.81 0.001 Undetectable - -
Peak blood glucose on CPB 0.91 0.86–0.96 0.001 160 mg/dl 84% 83%
CPB duration 0.80 0.68–0.89 0.001 96 minutes 74% 80%
AUC, area under the curve; CI, confidence interval; CPB, cardiopulmonary bypass; Do2, oxygen delivery.
Table 4
Subgroup analysis for peak blood lactates and lowest Do2 on CPB
No HL or HG HL alone HG alone HL and HG
(n = 374) (n = 4) (n = 69) (n = 23)
Peak blood lactate (mmol/l) 1.27 ± 0.46a 3.42 ± 0.85b 1.62 ± 0.61c 5.82 ± 3.34d
Lowest Do2 (ml/minute per m2) 294 ± 41 294 ± 53 287 ± 44 255 ± 62e
ap < 0.01 versus the other three groups; bp < 0.01 versus groups HG alone and HL plus HG; cp < 0.01 versus groups HL alone and HL plus HG; 
dp < 0.01 versus groups HL alone and HG alone; ep < 0.01 versus group no HL or HG and p = 0.014 versus group HG alone. CPB, 
cardiopulmonary bypass; Do2, oxygen delivery; HG, hyperglycemia; HL, hyperlactatemia.Critical Care    Vol 10 No 6    Ranucci et al.
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nificantly associated with a number of morbid events and with
mortality. However, the above data are not corrected for the
other explanatory variables. When included into a multivariable
model, general morbidity and mortality remained significantly
associated with HL during CPB; unfortunately, the authors
failed to indicate the odds ratios for both of the multivariable
logistic regressions applied, making a comparison between
their results and our results impossible. Our data suggest that
HL is associated with morbidity but not with mortality; given
that HL is more frequent in the presence of comorbidities and/
or prolonged CPB time, the inclusion of these covariates into
the predictive models reduces, but does not abolish, the role
of HL during CPB in deteriorating the postoperative outcome
in cardiac surgery. Of course, we cannot exclude that in a
larger cohort of patients, HL during CPB may be confirmed as
an independent risk factor for mortality too. Hyperglycemia not
accompanied by HL was not a morbidity/mortality risk factor in
our model.
As a final remark, we must consider that a CPB model of HL
and Do2 offers some experimental advantages. Both the hemo-
globin content and the pump flow are under the control of the
operator and may be modulated by intervention. This was not
the case with the present observational study, but this model
could be used for future interventional studies. However, even
if the study was conducted following the generally accepted
standards of CPB management, some very low values of Do2
were observed (3% of the patients had a lowest Do2 < 200 ml/
minute per m2) and these were related mainly to a pronounced
hemodilution.
Conclusion
HL during CPB is due mainly to a Do2 inadequate to fulfill the
metabolic needs of the patient, and this critical value is approx-
imately 260 ml/minute per m2. This 'circulatory shock' condi-
tion is associated with a reactive hyperglycemia that is
probably due to insulin resistance triggered by a catecho-
lamine release. The above condition plays a significant role in
deteriorating the postoperative outcome. Therefore, every
attempt should be applied to avoid HL during CPB, and the
critical Do2 value of 260 to 270 ml/minute per m2 should be
considered whenever setting the pump flow and the maximum
acceptable hemodilution degree.
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Table 5
Hyperlactatemia during CPB and postoperative outcome
Univariate analysis (Student's t test) Correcteda values
Outcome variable No HL (n = 443) HL (n = 27) pP
Peak serum creatinine (mg/dl) 1.3 ± 1.1 2.1 ± 1.4 0.001 0.45
MV time (hours) 22.6 ± 55 57.4 ± 68 0.015 0.41
ICU stay (days) 2.5 ± 3.4 5.3 ± 5.4 0.012 0.04
Univariate analysis (RR) Correctedb values
Outcome variable No HL (n = 443) HL (n = 27) RR (95% CI) OR (95% CI)
Prolonged (> 7 days) ICU stay 18 (4.1%) 5 (18.5%) 5.3 (1.8–15.8) 4.2 (1.04–17)
Prolonged (> 48 hours) MV 21 (4.7%) 9 (33.3%) 10 (4–25) 4.9 (1.6–15)
Surgical revision 19 (4.3%) 5 (18.5%) 5.1 (1.7–14.8) 2.5 (0.6–9.5)
Intra-aortic balloon pump 2 (0.4%) 3 (11.1%) 27.5 (4.4–172) 23 (2.7–207)
Atrial fibrillation 75 (17%) 9 (33.3%) 2.4 (1.06–5.6) 1.6 (0.6–4.1)
Severe lung dysfunction 6 (1.3%) 2 (7.4%) 5.8 (1.1–30.3) 0.8 (0.1–8.5)
Sepsis 9 (2%) 3 (11.1%) 6 (1.5–23.7) 3.6 (0.6–21)
Composite morbidity index 36 (8.1%) 9 (33.3%) 5.6 (2.4–13.5) 2.9 (1.03–8.5)
Hospital mortality 5 (1.1%) 3 (11.1%) 10.9 (2.5–48) 2.5 (0.37–18)
aValues obtained including preoperative serum creatinine value, active endocarditis, and CPB duration into a multivariate linear regression; bvalues 
obtained including preoperative serum creatinine value, active endocarditis, and CPB duration into a multivariate logistic regression. CI, 
confidence interval; CPB, cardiopulmonary bypass; HL, hyperlactatemia; ICU, intensive care unit; MV, mechanical ventilation; OR, odds ratio; RR, 
relative risk.Available online http://ccforum.com/content/10/6/R167
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Key messages
￿  Non-pre-existing HL during CPB for cardiac operations 
in adults occurs in approximately 6% of the patients.
￿  It is favored by the preoperative risk profile (high serum 
creatinine values and active endocarditis) and by pro-
longed (> 96 minutes) CPB times.
￿  It is triggered by an inadequate Do2 and generally 
appears when the Do2 is less than 260 to 270 ml/
minute per m2.
￿  It is associated with hyperglycemia.
￿  It is associated with an increased postoperative morbid-
ity but not with mortality.